Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Pharmacogenetics and Pharmacogenomics

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1655722

This article is part of the Research TopicPharmacogenomics of Drug Hypersensitivity ReactionsView all articles

The prevalence of Ggenetic variants of the Mas-related G-proteincoupled receptor X2 in patients experiencing does not explain perioperative hypersensitivity reactions to neuromuscular blocking agents

Provisionally accepted
  • 1Jagiellonian University Medical College, Department of Clinical and Environmental Allergology, Krakow, Poland
  • 2Jagiellonian University, Faculty of Biochemistry, Biophysics and Biotechnology, Krakow, Poland
  • 3University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia
  • 4Doctoral School of Exact and Natural Sciences, Jagiellonian University, Krakow, Krakow, Poland
  • 5Jagiellonian University, Faculty of Chemistry, Krakow, Poland
  • 6GENNET, Prague, Czechia
  • 7University Hospital Hradec Králové, Hradec Kralove, Czechia
  • 8Center of Environmental Allergology, University Hospital in Krakow, Krakow, Poland
  • 9Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia in Katowice, Katowice, Poland

The final, formatted version of the article will be published soon.

Background: Neuromuscular blocking agents (NMBAs) may induce life-threatening perioperative hypersensitivity reactions (POH). In addition to the known IgE-dependent allergic background, a mechanism dependent on Mas-Related G Protein-Coupled Receptor-X2 (MRGPRX2) on mast cells has been postulated. This does not explain why NMBA-induced POH is sporadic and only occurs in some patients. We hypothesised that this phenomenon depends on single nucleotide polymorphisms (SNPs) in MRGPRX2 that enhance the response to NMBA. Methods: The protein coding sequence of the MRGPRX2 gene was sequenced in 31 patients with NMBA-induced POH and 42 controls. Medical history and skin tests were used to diagnose patients. Based on basophil activation test (BAT) and specific IgE, patients were classified as having a history of IgE-mediated or likely MRGPRX2-mediated reactions. Severity of POH was defined according to a commonly accepted scale. Molecular dynamics simulations were conducted to assess the functional and structural effects of the SNPs.Results: The most common causative drugs were rocuronium (n=17) and atracurium (n=7), the others were cisatracurium, vecuronium, suxamethonium (n=2 each) and pipecuronium (n=1). We detected one missense SNP: N62S, present in 38.7% of the study group and in 45.2% of the controls. Prevalence of this SNP in patients was not dependent on causative drug, BAT and sIgE results, or severity of POH or its skin manifestations. Analysis of root mean square deviation and fluctuation plots showed no significant differences between wild-type and N62S variants.Conclusions: SNPs detected within the protein coding sequence of the MRGPRX2 gene were not risk factor in NMBA-induced POH, regardless of the clinical characteristics of the patients and the causative drug in question.

Keywords: genetic variants, Mast Cells, MRGPRX2, Neuromuscular Blocking Agents, Perioperative anaphylaxis, perioperative hypersensitivity

Received: 28 Jun 2025; Accepted: 28 Jul 2025.

Copyright: © 2025 Dziadowiec, Kwitniewski, Kopac, Rybka, Sedlackova, Srotova, Dyga, Gluck, Kitel and Porebski. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Grzegorz Porebski, Jagiellonian University Medical College, Department of Clinical and Environmental Allergology, Krakow, Poland

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.